The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksNetscientific Regulatory News (NSCI)

Share Price Information for Netscientific (NSCI)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 62.50
Bid: 60.00
Ask: 65.00
Change: -0.50 (-0.79%)
Spread: 5.00 (8.333%)
Open: 63.00
High: 63.00
Low: 62.50
Prev. Close: 63.00
NSCI Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

PDS equity issue and related party transaction

12 Feb 2020 11:07

RNS Number : 7809C
NetScientific PLC
12 February 2020
 

NetScientific plc

 

("NetScientific" or the "Company")

 

PDS Biotechnology equity issue and related party transaction

 

NetScientific plc ("NetScientific", AIM:NSCI) the transatlantic healthcare IP commercialisation group, announces that its portfolio company PDS Biotechnology Corporation ("PDS") (Nasdaq: PDSB) has today announced an issue of 9,230,770 new shares of common stock to raise gross proceeds of approximately US$12 million ("New Issue"), before deducting underwriting discounts, commissions and other offering expenses. The offering is expected to close on Friday, February 14, 2020, subject to customary closing conditions.

 

NetScientific currently owns 542,000 shares of PDS' common stock, representing approximately 10.28% of its undiluted share capital. The Board of NetScientific believes that PDS has strong prospects. It has therefore agreed to subscribe US$650,000 for 500,000 shares of common stock in the New Issue. Upon completion of the New Issue, NetScientific expects to own 1,042,000 shares of PDS' common stock, representing approximately 7.18% of the undiluted share capital.

 

NetScientific has cash to fund this investment, however for prudent financial management is entering into an 18 month secured £500,000 loan facility with Beckman Group. The facility, which incurs interest of 10.0% pa on drawn amounts and 3.0% pa on undrawn amounts and has an arrangement fee of 1%, can be extended by mutual agreement for an additional 6 months, and is secured on the whole of NetScientific's interest in PDS.

 

As Beckman Group is associated with M A Lawson, who is interested in 29.98 % of NetScientific's issued share capital, the secured loan facility represents a related party transaction in accordance with Rule 13 of the AIM Rules for Companies. The Directors of NetScientific consider, having consulted the Company's nominated adviser, that the terms of the facility are fair and reasonable insofar as its shareholders are concerned.

 

For more information, please contact:

NetScientific Tel: 020 3514 1800

Ian Postlethwaite, CEO and CFO

 

WH Ireland (NOMAD and Broker) Tel: 020 7220 1666

Chris Fielding / Darshan Patel

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
MSCSFLFFEESSESE
Date   Source Headline
19th Mar 20187:00 amRNSWanda Expanding to Orthopedic Analytics
13th Mar 20187:00 amRNSVortex Announces Partnership with BioView
15th Feb 20187:00 amRNSProAxsis Reports First NEATstik Sale
9th Feb 20187:00 amRNSVortex Releases Publication in Nature Scientific
16th Jan 20187:00 amRNSNetScientific Portfolio Update
8th Jan 20187:00 amRNSProAxsis Achieves CE Mark for Plasmin Immunoassay
4th Jan 20187:00 amRNSGlycotestT Completes Diagnostic Evaluation
12th Dec 20177:00 amRNSWanda Awarded Two Patents
21st Nov 20177:00 amRNSProAxsis: Sales Update
7th Nov 20177:00 amRNSVortex Announces First Commercial VTX-1 Sale
2nd Nov 20177:00 amRNSGlycotest Adds Allowed Chinese Patent to Portfolio
1st Nov 201711:00 amRNSVortex Announces Liquid Biopsy Study in NPJ
30th Oct 20177:00 amRNSProAxsis Showcases ProteaseTag® Research at NACFC
27th Oct 20177:00 amRNSProAxsis Partnership - US National Jewish Health
25th Oct 20177:00 amRNSDirectorate Change
5th Oct 20177:00 amRNSGlycotest Granted Japanese Patent
2nd Oct 20177:00 amRNSWanda Awarded US Patent
28th Sep 20177:00 amRNS2017 Interim Results
14th Sep 20177:00 amRNSProAxsis appoints Diagenics Limited as Distributor
11th Sep 20177:00 amRNSProAxsis Signs Partnership: Biotechnology Company
7th Sep 20177:00 amRNSNotice of Interim Results
4th Sep 20177:00 amRNSProAxsis is awarded a European CE Mark
24th Jul 20177:00 amRNSProAxsis awarded a Significant Innovate UK Grant
10th Jul 201712:00 pmRNSPDS Announces Clinical Collaboration with Merck
7th Jul 20177:00 amRNSGlycotest Strengthens Intellectual Property Reach
26th Jun 20177:00 amRNSGlycotest Update
21st Jun 201712:00 pmRNSResult of AGM
16th Jun 201710:05 amRNSHoldings in Company
15th Jun 20172:52 pmRNSHoldings in Company
12th Jun 201712:02 pmRNSResults of General Meeting
12th Jun 201711:10 amRNSResult of Placing
26th May 20173:52 pmRNSNotice of AGM and Annual Report & Accounts
26th May 201712:49 pmRNSResults of Placing and Subscription
25th May 201711:51 amRNSProposed Placing and Subscription
24th May 20177:00 amRNSVortex Initiates Clinical Research Studies
10th May 20177:00 amRNSProAxsis announces additional IP
5th May 20177:00 amRNSProAxsis Presents New Data at Major US Conference
24th Apr 20177:00 amRNSBTG purchases Wanda's shares in Oncoverse
3rd Apr 20177:00 amRNSFull Year Results for the year ended 31 Dec 2016
31st Mar 20177:00 amRNSVortex Biosciences Announces Publications
27th Mar 20177:00 amRNSNotice of Preliminary Results
22nd Feb 20177:00 amRNSVortex Biosciences Launches VTX-1 Liquid Biopsy
15th Feb 20177:00 amRNSVortex Biosciences' CSO Wins SLAS Innovation Award
9th Feb 20177:00 amRNSVortex Biosciences' CSO Finalist for SLAS Award
30th Jan 20177:00 amRNSGrant of Options to Directors
20th Dec 20167:00 amRNSNew CEO appointed to Wanda
16th Dec 20167:00 amRNSExecuted Warrants
18th Nov 20167:00 amRNSNetscientific: Vortex Biosciences Analysis Data
3rd Nov 20164:34 pmRNSVortex Gains CE Mark and FDA Class 1 Registration
26th Oct 201612:30 pmRNSVortex Biosciences Appoints Non-Executive Director

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.